Chi-Med’s Surufatinib Receives the US FDA’s Fast Track Designations for Pancreatic and Non-Pancreatic Neuroendocrine Tumors

 Chi-Med’s Surufatinib Receives the US FDA’s Fast Track Designations for Pancreatic and Non-Pancreatic Neuroendocrine Tumors

Shots:

  • The US FDA has granted FT designation to Chi-Med’s surufatinib for the treatment of both advanced and progressive pancreatic NET and non-pancreatic NET in patients who are not amenable for surgery
  • Based on two P-III studies and ongoing P-Ib study, the company is planning for regulatory interactions in the US, EU and Japan. In Nov’2019, NMPA has accepted the NDA for the therapy to treat non-pancreatic NET and granted PR designation in Dec’2019
  • Surufatinib is a novel, oral angio-immuno kinase inhibitor act by inhibiting the tyrosine kinase activity associated with VEGFR and FGFR and has received FDA’s ODD for pancreatic NET in Nov’2019

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Chi-Med

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post